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The Stromal Cell–Derived
Factor-1/CXCR4 Axis in
Cardiac Injury and Repair*
Nikolaos G. Frangogiannis, MD
New York, New York
Chemokines are chemotactic cytokines that direct cellular
migration through interactions with their cognate chemo-
kine receptors. Most chemokines are not expressed in the
normal myocardium, but are up-regulated and secreted in
the infarcted heart (1), where they play an important role in
leukocyte recruitment (2). Stromal cell– derived factor
SDF)-1/CXCL12 and its main receptor CXCR4 are a
hemokine/chemokine receptor pair with unique functions
n myocardial biology. Constitutive SDF-1/CXCR4 signal-
ng in the myocardium is essential for cardiac development.
See page 2415
Mice with targeted deletion of SDF-1 or CXCR4 exhibit
embryonic lethality associated with impaired vascular for-
mation and the development of ventricular aortopulmonary
septum defects (3). In addition to its role in cardiovascular
development, a growing body of evidence suggests that the
SDF-1/CXCR4 axis is rapidly activated in the healing
infarct (4), where it may exert protective actions by promot-
ing angiogenesis, transducing prosurvival signals in cardio-
myocytes, and enhancing the regenerative capacity of mo-
bilized progenitor cells. Over the past 10 years, numerous
studies have investigated the role of endogenous SDF-1/
CXCR4 signaling in the repair of the infarcted heart and
have explored the effects of SDF-1–based therapies in
experimental myocardial infarction. The experiments have
produced somewhat contradictory results, highlighting the
complex, cell type–specific, and context-dependent actions
of SDF-1/CXCR4 signaling in the infarcted heart.
In this issue of the Journal, Liehn et al. (5) studied the
role of endogenous CXCR4 signaling in a model of non-
reperfused myocardial infarction. Because CXCR4-null
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Cxcr4/ animals, which are phenotypically normal, but
xhibit significantly lower cell surface Cxcr4 expression.
hen compared with wild-type animals, Cxcr4/ mice
ad significantly reduced baseline coronary flow and exhib-
ted impaired neoangiogenesis in the infarcted heart. Sur-
risingly, reduced coronary perfusion in Cxcr4/ animals
had no adverse functional consequences; Cxcr4/ and
ild-type animals had comparable post-infarction dysfunc-
ion and exhibited no difference in the density of apoptotic
ardiomyocytes. The scars in Cxcr4/ animals were
smaller, probably reflecting accelerated wound contraction,
and the leukocyte infiltrate in the infarcted heart contained
fewer neutrophils and proinflammatory monocytes and an
increased number of reparative Gr-1low monocytic cells.
The findings highlight the pleiotropic effects of CXCR4
signaling, suggesting that in the infarcted myocardium, the
beneficial effects of CXCR4-dependent angiogenesis may
be counterbalanced by its proinflammatory actions. More-
over, the study illustrates the limitations of genetically
targeted mice in dissecting the pathophysiologic basis of
disease. Attenuated CXCR4 signaling in heterozygotic
animals was associated with a marked reduction in baseline
cardiac perfusion that may have altered the susceptibility of
cardiomyocytes to ischemic injury. These baseline altera-
tions in cardiac physiology hamper understanding of the
role of CXCR4 in ischemic injury, representing a significant
challenge in interpretation of the findings. Despite these
limitations, the study contributes new insights into the role
of CXCR4 signaling in cardiac repair, providing evidence of
both beneficial and detrimental effects of activation of the
SDF-1/CXCR4 axis. Because CXCR4 signaling is a prom-
ising therapeutic target in myocardial infarction, several
distinct experimental approaches have been used to explore
its biological effects in the healing infarct.
Gain-of-function and pharmacologic inhibition experi-
ments have served as the main tools with which to study the
role of SDF-1/CXCR4 in cardiac repair; recently, condi-
tional targeting approaches have also been used (Table 1)
(6–17). In most studies, local infusion or overexpression of
SDF-1 in the infarcted heart attenuated systolic dysfunction
and reduced adverse remodeling. Three potential mecha-
nisms of benefit have been suggested. First, SDF-1–
mediated CXCR4 signaling may enhance infarct angiogen-
esis (6–9) through recruitment of endothelial progenitor
cells (EPCs) or direct activation of angiogenic pathways.
Second, SDF-1/CXCR4 signaling may protect ischemic
cardiomyocytes from apoptosis through actions involving
Erk and Akt activation (10). Third, SDF-1 may promote
regeneration through recruitment of Cxcr4/c-kit progen-
tor cells (8). In contrast to the protective effects observed in
ost studies, an investigation using adenovirus-mediated
ene therapy reported that CXCR4 overexpression in the
nfarcted heart accentuated inflammatory injury and in-
n mode
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Pharmacologic inhibition of SDF-1/CXCR4 signaling
using the selective small-molecule CXCR4 antagonist
AMD3100 has also produced conflicting results. Long-term
continuous inhibition of the SDF-1/CXCR4 axis in mice
undergoing nonreperfused infarction protocols exacerbated
systolic dysfunction and cardiac remodeling after infarction
(12); these findings are consistent with the protective
actions of CXCR4 signaling suggested by most gain-of
function studies. However, other investigations demon-
strated beneficial effects of CXCR4 antagonism. AMD3100
administration reduced infarct size and improved systolic
function (13) in a rat model; however, the basis for these
effects was not investigated. A recent investigation demon-
strated that, although a single-dose AMD3100 injection
administered after the onset of myocardial infarction preserved
cardiac function, continuous infusion worsened the outcome
(14). The beneficial effects of early CXCR4 antagonism were
associated with increased mobilization of EPCs from the bone
Experimental Studies Examining the Effects of SDF-1/CXCR4 SignTable 1 Experimental Studies Examining the Effects of SDF-1/
Strategy Used Model
Gain-of-function studies
Intramyocardial SDF-1 injection (300 ng)
at the time of occlusion
Mouse (NR) SDF
a
Intramyocardial SDF-1 injection (1 g) during occlusion Mouse (NR) SDF
e
Intraventricular SDF-1 injection (35 g/kg/min)
for 5 min before occlusion
Mouse (R) SDF
Intramyocardial injection of a protease-resistant SDF-1 Rat (NR) SDF
p
Systemic infusion of SDF-1–overexpressing MSCs
1 day post-infarction
Rat (NR) SDF
c
Systemic infusion of CXCR4 MSCs 3 days post-infarction Rat (NR) CXC
w
Transplantation of SDF-1–overexpressing fibroblasts
8 weeks after infarction
Rat (NR) SDF
st
Adenovirus-mediated CXCR4 gene therapy 1 week
before coronary occlusion
Rat (R) CXC
c
Adenovirus-mediated SDF-1 overexpression 4 h
post-infarction in animals receiving
bone marrow-derived cells
Mouse (NR) SDF
in
Pharmacologic inhibition studies
Continuous subcutaneous infusion with the CXCR4
inhibitor AMD3100 for 20 days after occlusion
Mouse (NR) Inhib
a
Intraperitoneal and oral treatment with AMD3100 Rat (NR) Inhib
a. Single-dose AMD3100 injection after the onset of
infarction;
b. continuous AMD3100 infusion
Mouse Acut
in
C
in
Genetic loss-of-function studies
Mice with congenital and conditional deletion of
cardiomyocyte CXCR4 underwent infarction protocols
Mouse (NR) Disru
a
CXCR4/ mice underwent infarction protocols Mouse (NR) Atte
A
in
n
EPC  endothelial progenitor cell; MSC  mesenchymal stem cell; NR  nonreperfused infarctiomarrow. In contrast, the detrimental effects of long-termCXCR4 inhibition may be due to impaired incorporation of
EPCs in the ischemic border zone (14).
The conflicting findings of studies interfering with the
SDF-1/CXCR4 axis in the infarcted heart are due to the
multifunctional and pleiotropic effects of CXCR4 signaling
and to the complexity of the reparative process. CXCR4
signaling modulates phenotype and function of all cell types
involved in cardiac repair; thus, in the dynamic environment of
the healing infarct, functional outcome of strategies targeting
the SDF-1/CXCR4 axis depends on timing and on the spatial
localization of the intervention. Moreover, dose-dependent
effects of SDF-1 on various cell types may affect the balance
between angiogenic/reparative and proinflammatory actions of
CXCR4 signaling. Dissection of cell- and time-specific effects
of CXCR4 activation using conditionally targeted mice would
be an important step for understanding the role of SDF-1
signaling in myocardial infarction. Using this type of approach,
Agarwal et al. (15) demonstrated that CXCR4 signaling in
cardiac myocytes does not play a crucial role in cardiac
remodeling. Further work is needed to study the role of
in Myocardial Infarction4 Signaling in Myocardial Infarction
Main Findings Ref. #
apy improved systolic function, enhancing cardiomyocyte survival
easing infarct angiogenesis.
(6)
apy improved systolic function, reduced infarct size, and
d angiogenesis.
(9)
tment reduced infarct size. (10)
apy improved systolic function, inducing recruitment of CXCR4
or cells and increasing angiogenesis.
(8)
ressing MSCs increased angiogenesis and enhanced
yocyte survival.
(7)
rexpressing MSCs had attenuated cardiac dysfunction associated
iogenesis and myogenesis.
(16)
ressing fibroblasts induced homing of filgastrim-mobilized CD117
lls into the myocardium and improved cardiac function.
(4)
rexpression accentuated myocardial inflammation, increased
yocyte apoptosis, and worsened cardiac dysfunction.
(11)
expression increased recruitment of bone marrow–derived cells
farct.
(17)
f the SDF-1/CXCR4 axis accentuated dysfunction and
remodeling.
(12)
f SDF-1/CXCR4 reduced infarct size and improved ventricular function. (13)
R4 antagonism improved survival and reduced cardiac remodeling,
ng mobilization and recruitment of EPCs. In contrast, long-term
inhibition accentuated adverse remodeling and impaired EPC
ation in the infarct border zone.
(14)
ardiomyocyte CXCR4 signaling did not affect cardiac repair
odeling.
(15)
CXCR4 signaling was associated with reduced basal coronary flow.
arction, CXCR4/ mice had reduced angiogenesis and enhanced
atory activity. The severity of post-infarction systolic dysfunction was
cted by reduced CXCR4 signaling.
(5)
l; R  reperfused infarction model; SDF  stromal cell–derived factor.alingCXCR
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SDF-1 in Myocardial Infarction November 29, 2011:2424–6tions in endothelial cells and leukocytes. Beyond their obvious
mechanistic significance, such investigations would allow a
more rational design of SDF-1–based strategies for patients
with myocardial infarction.
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